All News

In part 2, Staci-Marie Norman, PharmD, CDCES, FAPhA, and Susan Cornell, PharmD, CDCES, FAPhA, FADCES, discuss the pharmacist’s ability to meander a booming medication class in GLP-1s.

FDA leadership shifts as Marty Makary resigns amid drug, vaccine and mifepristone disputes; Kyle Diamantas steps in as acting commissioner.

Pharmacists expand into vaccines and telehealth, but state laws and reimbursement gaps persist.

Despite common trends in the specialty drug market persisting, a new pharmacy landscape must come together to address rising issues.

Preventing pneumococcal disease remains a cornerstone of public health, yet the strategy for protection is increasingly individualized and complex.

ECO 2026 data shows Wegovy cuts migraines, depression, and heart risk in menopausal women, as glucagon-like peptide-1s' demand challenges pharmacists.

Beyond medications, lifestyle modifications can also help patients curb allergy symptoms.

Opioid pain care shifts fast, and pharmacists and pharmacies lead safer prescribing, naloxone education, and monitoring to curb overdose deaths.

This episode explores the differences between behavior that is caught rather than taught, explaining how leadership can be a learned skill if properly approached.

Researchers explore invasive pneumococcal disease epidemiology after the introduction of multiple pneumococcal conjugate vaccines.

New research shows inflammation and diabetes raise preterm birth risk, suggesting C-reactive protein testing.

The weight-loss and diabetes drug will now be available via Amazon Pharmacy for same-day delivery or in-person kiosk pickup.

Medicare’s new GLP‑1 bridge program launches soon, easing access without shortages, and pharamcists are at the focal point of these transitions.

As artificial intelligence becomes commonplace in medical practice, officials are gradually uncovering significant safety risks.

By late February 2026, national data from the CDC reveal a test positivity rate of 9.1%, the highest recorded for the entire season at that point.

With value-based care initiatives on the rise in the US health care system, one partnership in Ohio is showing early signs of significant success.

CMS pilots BALANCE and GLP-1 Bridge models to widen Medicare/Medicaid obesity drug coverage, spotlighting pharmacists’ role in access and safe therapy.

Exploring data across a variety of income settings, researchers conduct a review of invasive pneumococcal disease carriage, cases, and their associations.

A PQA program shows how value-based pharmacy contracts, shared metrics, and better data boost immunizations and patient outcomes beyond dispensing.

Episode 10 explores recent guideline changes in clinicians’ management of dyslipidemia, highlighting much more than a few updated recommendations.

In part 2, Kevin Day, PharmD, breaks down the Pharmacy Quality Rewards Program and its push toward value-based care in pharmacy practice.

As accessible and trusted health care providers, pharmacists have important roles to play in helping patients mitigate the impact of heat on their health.

Exploring clinical prioritization and macroeconomic investment, researchers examine the link between disease and economic burden of diabetes.

GLP-1 prescriptions surge to nearly 8% of fills, fueled by weight-loss demand.

With continued pressure for federal action regarding the abortion drug mifepristone, SCOTUS blocked a previous decision that would limit the pill’s access.

FDA clears Langlara interchangeable insulin glargine, enabling pharmacy substitution for Lantus and widening affordable basal insulin access.

Because pharmacists can review both prescription and refill histories, they are uniquely positioned to spot patterns of underuse or overuse of allergy and asthma medications.

Despite WHO officials stating that risks from the outbreak remain low, experts are acting urgently to uncover details and provide support.